Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Biology of FasL.

Lee HO, Ferguson TA.

Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):325-35. Review.

PMID:
12787569
2.

Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology.

Brunner T, Wasem C, Torgler R, Cima I, Jakob S, Corazza N.

Semin Immunol. 2003 Jun;15(3):167-76. Review.

PMID:
14563115
3.

The role of Fas/FasL interactions in the regulation of B cell function.

Jacobson BA, Rothstein TL, Marshak-Rothstein A.

Behring Inst Mitt. 1996 Oct;(97):185-99. Review.

PMID:
8950476
4.

CD95 (APO-1/Fas) and its ligand in the mouse immune system.

Mariani SM, Matiba B, Krammer PH.

Behring Inst Mitt. 1996 Oct;(97):12-23. Review. No abstract available.

PMID:
8950464
5.

Die and let live: eliminating dangerous lymphocytes.

Abbas AK.

Cell. 1996 Mar 8;84(5):655-7. Review. No abstract available.

6.

The role of Fas ligand in immune privilege.

Green DR, Ferguson TA.

Nat Rev Mol Cell Biol. 2001 Dec;2(12):917-24. Review.

PMID:
11733771
7.

Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system.

Li-Weber M, Krammer PH.

Semin Immunol. 2003 Jun;15(3):145-57. Review.

PMID:
14563113
8.

CD95L/FasL and TRAIL in tumour surveillance and cancer therapy.

Wajant H.

Cancer Treat Res. 2006;130:141-65. Review.

PMID:
16610707
9.

Induction of tolerance using Fas ligand: a double-edged immunomodulator.

Askenasy N, Yolcu ES, Yaniv I, Shirwan H.

Blood. 2005 Feb 15;105(4):1396-404. Epub 2004 Oct 14. Review.

10.

The Fas/Fas ligand system and cancer: immune privilege and apoptosis.

Abrahams VM, Kamsteeg M, Mor G.

Mol Biotechnol. 2003 Sep;25(1):19-30. Review.

PMID:
13679631
11.

Tumor counterattack: fact or fiction?

Igney FH, Krammer PH.

Cancer Immunol Immunother. 2005 Nov;54(11):1127-36. Epub 2005 May 12. Review.

PMID:
15889255
13.

Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells.

Screpanti V, Wallin RP, Grandien A, Ljunggren HG.

Mol Immunol. 2005 Feb;42(4):495-9. Review.

PMID:
15607805
14.

Slowly getting a clue on CD95 ligand biology.

Linkermann A, Qian J, Janssen O.

Biochem Pharmacol. 2003 Oct 15;66(8):1417-26. Review.

PMID:
14555216
15.

[Apoptosis in T-lymphocytes and its significance].

Graban J, KohĂșt A.

Cesk Fysiol. 2003 Dec;52(4):144-52. Review. Slovak.

PMID:
15027147
16.

Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response.

Abrams SI.

Front Biosci. 2005 Jan 1;10:809-21. Print 2005 Jan 1. Review.

PMID:
15569621
17.

Considering Fas ligand as a target for therapy.

Linkermann A, Qian J, Lettau M, Kabelitz D, Janssen O.

Expert Opin Ther Targets. 2005 Feb;9(1):119-34. Review.

PMID:
15757486
18.

The Fas signalling pathway and its role in the pathogenesis of cancer.

Houston A, O'Connell J.

Curr Opin Pharmacol. 2004 Aug;4(4):321-6. Review.

PMID:
15251123
19.

Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses.

Choi C, Benveniste EN.

Brain Res Brain Res Rev. 2004 Jan;44(1):65-81. Review.

PMID:
14739003
20.

The role of Fas/FasL in immunosuppression induced by human tumors.

Whiteside TL, Rabinowich H.

Cancer Immunol Immunother. 1998 Jun;46(4):175-84. Review. No abstract available.

PMID:
9671140
Items per page

Supplemental Content

Write to the Help Desk